Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Hongyan Wang, Ping Chen, Ph.D., Jiang Wang, Ramasamy Santhanam, Ph.D, Josephine Aimiuwu, Vijayasaradhi UV, Zhongfa Liu, Sebastian Schwind, MD, Alice S. Mims, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Michael R. Grever, MD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Ramiro Garzon, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3578.

https://doi.org/10.1182/blood.V120.21.3578.3578

Published: 2012

Journal Articles

Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia

Jane L. Liesveld, MD, Kristen O'Dwyer, MD, Michael W. Becker, MD, Deborah Mulford, MD, Alison Walker, MD, Rui Chen, PhD, Jeremy Bechelli, MS, Karen Rosell, BS, Craig T. Jordan, PhD, Mohammad Minhajuddin, PhD, Gordon L. Phillips, II, MD

Blood (2012) 120 (21): 3549.

https://doi.org/10.1182/blood.V120.21.3549.3549

Published: 2012

Journal Articles

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Rebecca B Klisovic, MD, Hongyan Wang, Alison Walker, MD, Katherine Walsh, MD, Sumithira Vasu, MBBS, Ramiro Garzon, MD, Steven M. Devine, MD, Jiang Wang, Celia Garr, RN, Adam Norris, John C. Byrd, MD, Michael R. Grever, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3616.

https://doi.org/10.1182/blood.V120.21.3616.3616

Published: 2012

Journal Articles

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

William Blum, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Sebastian Schwind, MD, Yao Jiang, Jiang Wang, Mitch Phelps, PhD, Susan Geyer, PhD, Steven M. Devine, MD, Kathy Walsh, MD, Sumithira Vasu, MBBS, John P. Curfman, Larry Schaaf, PhD, Celia Garr, RN, Cheryl Kefauver, RN, John C. Byrd, MD, Michael R. Grever, MD, Ramiro Garzon, MD, Guido Marcucci, MD

Blood (2012) 120 (21): 2619.

https://doi.org/10.1182/blood.V120.21.2619.2619

Published: 2012

Journal Articles

Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias

Ivana Gojo, MD, Alison Walker, MD, Maureen Cooper, MD, Eric J Feldman, MD, Swaminathan Padmanabhan, MBBS, MS, Maria R Baer, MD, Jennifer Poon, PharmD, Karen Small, BSN, Da Zhang, MS, Mariola Sadowska, PhD, Rajat Bannerji, MD, PhD

Blood (2010) 116 (21): 3287.

https://doi.org/10.1182/blood.V116.21.3287.3287

Published: 2010

Journal Articles

Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)

William Blum, MD, Rebecca B. Klisovic, MD, Ramiro Garzon, MD, Alison Walker, MD, Sebastian Schwind, MD, Shujun Liu, PhD, Larry Schaaf, PhD, Celia Garr, RN, Steven M. Devine, MD, Michael R. Grever, MD, John C. Byrd, MD, Guido Marcucci, MD

Blood (2010) 116 (21): 3293.

https://doi.org/10.1182/blood.V116.21.3293.3293

Published: 2010

Journal Articles

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Jason C. Chandler, MD, Rebecca B. Klisovic, MD, Mitch A. Phelps, PhD, Alison Walker, MD, Ramiro Garzon, MD, Xiaoxia Yang, Larry Schaaf, PhD, Sebastian Schwind, MD, Heiko Becker, MD, Shujun Liu, PhD, Chris Hickey, Cheryl Kefauver, RN, Jon Mickle, CNP, Steven M Devine, MD, Michael R. Grever, MD, John C. Byrd, MD, Guido Marcucci, MD, William Blum, MD

Blood (2009) 114 (22): 841.

https://doi.org/10.1182/blood.V114.22.841.841

Published: 2009

Journal Articles

Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML).

William Blum, MD, Rebecca B. Klisovic, MD, Alison Walker, MD, Ramiro Garzon, MD, Shujun Liu, PhD, Larry J. Schaaf, PhD, Kristina Humphries, Michael R. Grever, Steven M. Devine, MD, John C. Byrd, Guido Marcucci, MD,

Blood (2009) 114 (22): 2065.

https://doi.org/10.1182/blood.V114.22.2065.2065

Published: 2009

Journal Articles

The mTOR Inhibitor Rapamycin Demonstrates Activity Against AML in Combination with Imatinib Mesylate and with 5-Azacytidine.

Jane L. Liesveld, MD, Karen Rosell, BS, Chaohui Lu, BS, Deborah Mulford, MD, Alison Walker, MD

Blood (2007) 110 (11): 4318.

https://doi.org/10.1182/blood.V110.11.4318.4318

Published: 2007

Journal Articles

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Camille N. Abboud, MD, Alison Walker, MD, Rami S. Komrokji, MD, Jainulabdeen J. Ifthikharuddin, MD, Connie Sparks, BS,CRA, Kelly Likly, MSN, Patti Messina, BSN, Deborah Mulford, MD, Jonathan Friedberg, MD, Michael W. Becker, MD, Faith Young, MD, Steven H. Bernstein, MD, August J. Salvado, MD, Gordon L. Phillips, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 1958.

https://doi.org/10.1182/blood.V108.11.1958.1958

Published: 2006

NARROW

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias

Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML).

The mTOR Inhibitor Rapamycin Demonstrates Activity Against AML in Combination with Imatinib Mesylate and with 5-Azacytidine.

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only